Hematologic response at 30 and 90 days in stage IIIb AL amyloidosis. Survival according to the depth and quality of hematologic response at 30 days from treatment initiation: CR/VGPR median survival, 52 months; PR median survival, 16 months; and NR median survival, 3 months. (A) Survival according to the depth and quality of hematologic response at 90 days from treatment initiation: CR/VGPR median survival, 52 months; PR median survival, 16 months; and NR median survival, 6 months. (B) A 30- and 90-day landmark analysis was performed.